Rivaroxaban News and Research

RSS

New system improves blood thinner safety

Doctors and pharmacists treating people with blood thinners can reduce the rate of inappropriate dosing -; as well as blood clots and strokes that can result from it -; using an electronic patient management system, a study suggests.

17 Sep 2024

Cardiovascular risks of COVID-19 antivirals

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful consideration when prescribing these drugs to high-risk patients.

16 Sep 2024

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Study reveals common off-label dosing of direct oral anticoagulants

Millions of Americans take anticoagulants, commonly known as blood thinners. These medications work to prevent blood clots that cause heart attack and stroke.

31 Jul 2024

Ground falls most common cause of head injury in elderly, new study finds

Falls are the most common cause of injury among adults 65 and older in the United States. According to the U.S. Centers for Disease Control and Prevention, every year, more than 14 million older adults (one in four) report a fall. About 90% of head injuries among older individuals is due to ground-level falls.

26 Jun 2024

Low-dose direct oral anticoagulants linked to increased bleeding risk in Afib patients

Patients with atrial fibrillation (Afib) who took low doses of blood-thinning medications known as direct oral anticoagulants (DOACs) experienced more bleeding episodes during the first three months of treatment and about one in five had high blood levels of the medications, compared with similar patients who took standard doses of the same medications, according to a study published in Blood Advances.

6 Jun 2024

New joint guideline highlights importance of coordinated care for peripheral artery disease

Timely diagnosis and proper management of peripheral artery disease (PAD), including coordinated care from a multispecialty team, are essential to help prevent amputation and other cardiovascular complications and to allow patients with PAD to live longer lives with better physical function and improved quality of life, according to a new joint guideline published today in the American Heart Association's flagship, peer-reviewed journal Circulation and simultaneously in the Journal of the American College of Cardiology.

14 May 2024

Study: Most stroke survivors can safely take two types of common antidepressants

Most stroke survivors were able to safely take two types of common antidepressants, according to a preliminary study to be presented at the American Stroke Association's International Stroke Conference 2024.

1 Feb 2024

Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications

When diagnosed with a blood clot or atrial fibrillation, patients are often prescribed anticoagulants, or blood thinners, to prevent a future clot.

14 Dec 2023

Abelacimab significantly reduces bleeding risk in atrial fibrillation patients with stroke risk

An experimental anti-clotting medication, abelacimab, significantly reduced bleeding among people with atrial fibrillation (or AFib) who were at risk of stroke, according to results of the AZALEA-TIMI 71 trial, presented today as late-breaking science at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Modern blood thinners linked to reduced risk of bleeding

Modern blood-thinning drugs (known as NOACs) reduce the risk of serious bleeding by up to 45 percent compared to the traditional drug Waran in the treatment of blood clots in the legs and lungs.

29 Aug 2023

Do system-level DOAC therapy management services affect anticoagulation outcomes for AF patients compared to usual care?

Researchers compared outcomes related to three direct oral anticoagulant (DOAC) care models.

10 Jul 2023

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.

4 Jan 2023

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT).

27 Dec 2022

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).

27 Dec 2022

Rivaroxaban News and Research

New system improves blood thinner safety

Cardiovascular risks of COVID-19 antivirals

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

Study reveals common off-label dosing of direct oral anticoagulants

Ground falls most common cause of head injury in elderly, new study finds

Low-dose direct oral anticoagulants linked to increased bleeding risk in Afib patients

New joint guideline highlights importance of coordinated care for peripheral artery disease

Study: Most stroke survivors can safely take two types of common antidepressants

Common oral anticoagulant rivaroxaban linked to highest risk of bleeding complications

Abelacimab significantly reduces bleeding risk in atrial fibrillation patients with stroke risk

Modern blood thinners linked to reduced risk of bleeding

Do system-level DOAC therapy management services affect anticoagulation outcomes for AF patients compared to usual care?

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

No benefit of low dose apixaban following acute COVID-19

Additional six weeks of anti-clotting treatment reduces further clot risk after distal DVT

Study explores the effect of COVID-19 on platelet function

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News